BB Biotech AG

BION

Equity

ISIN CH0038389992 / Valor 3838999

SIX Swiss Exchange (2024-11-19)

CHF 36.00-0.83%

BB Biotech AG
UMushroom community rating:

5.00 3 votes No rating yet

NegativeNeutralPositive

About company

BB Biotech AG is a closed-end investment fund, which engages in investing in biotechnology companies. It focuses on the development and commercialization of novel drugs sectors. The company was founded on November 9, 1993 and is headquartered in Schaffhausen, Switzerland.

Summarized from source with an LLMView SourceSector: Technology

Income

BB Biotech AG reported a total comprehensive profit of CHF 260,494,000 for the first quarter of 2024, a significant turnaround from the loss of CHF 253,855,000 in the same period of 2023. This positive shift highlights the company's improved financial performance and strategic investments in the biotechnology sector.

Earnings Per Share

For the first quarter of 2024, BB Biotech AG's earnings per share (EPS) stood at CHF 4.75, compared to a loss per share of CHF 4.63 in the first quarter of 2023. This improvement in EPS reflects the company's enhanced profitability and effective cost management strategies.

Revenue by Geography

BB Biotech AG's profit before tax for the first quarter of 2024 was primarily driven by its investments in the USA, which contributed CHF 196,780,000. Other notable contributions came from the Netherlands (CHF 27,903,000) and Canada (CHF 16,544,000), indicating a strong performance across multiple regions.

Assets Pledged

As of March 31, 2024, BB Biotech AG had securities amounting to CHF 2,822.2 million pledged as collateral for a credit line of CHF 700 million. This is an increase from CHF 2,634.7 million in pledged securities as of December 31, 2023, reflecting the company's growing asset base and financial stability.

Administrative Expenses

BB Biotech AG's administrative expenses for the first quarter of 2024 totaled CHF 7,525,000, compared to CHF 8,943,000 in the same period of 2023. This reduction in administrative costs demonstrates the company's efforts to streamline operations and improve cost efficiency.

Summarized from source with an LLMView Source

Key figures

-7.10%1Y

-54.1%3Y

-45.6%5Y

Performance

21.7%1Y

25.8%3Y

26.8%5Y

Volatility